{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:21:14Z","timestamp":1790774474813,"version":"4.1.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["ZIA-DA000633"],"award-info":[{"award-number":["ZIA-DA000633"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["ZIA-DA000633"],"award-info":[{"award-number":["ZIA-DA000633"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["ZIA-DA000633"],"award-info":[{"award-number":["ZIA-DA000633"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["ZIA-DA000633"],"award-info":[{"award-number":["ZIA-DA000633"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["ZIA-DA000633"],"award-info":[{"award-number":["ZIA-DA000633"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["ZIA-DA000633"],"award-info":[{"award-number":["ZIA-DA000633"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["ZIA-DA000633"],"award-info":[{"award-number":["ZIA-DA000633"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse"},{"name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse"},{"name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse"},{"name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse"},{"name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse"},{"name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Peroxisome proliferator-activated receptors (PPARs) are a family of nuclear receptors that regulate gene expression. \u0394\n                    <jats:sup>9<\/jats:sup>\n                    -tetrahydrocannabinol (\u0394\n                    <jats:sup>9<\/jats:sup>\n                    -THC) is a PPAR\u03b3 agonist and some endocannabinoids are natural activators of PPAR\n                    <jats:italic>\u03b1<\/jats:italic>\n                    and PPAR\u03b3. However, little is known regarding their cellular distributions in the brain and functional roles in cannabinoid action. Here, we first used RNAscope in situ hybridization and immunohistochemistry assays to examine the cellular distributions of PPAR\u03b1 and PPAR\u03b3 expression in the mouse brain. We found that PPAR\u03b1 and PPAR\u03b3 are expressed in ~70% of midbrain dopamine (DA) neurons. In the amygdala, PPAR\u03b1 is expressed in ~60% of\u00a0glutamatergic neurons, while PPAR\u03b3 is expressed in ~60% \u00a0of\u00a0GABA neurons. However, no PPAR\u03b1\/\u03b3 signal was detected in GABA neurons in the nucleus accumbens. We then used a series of behavioral assays to determine the functional roles of PPAR\u03b1\/\u03b3 in the CNS effects of \u0394\n                    <jats:sup>9<\/jats:sup>\n                    -THC. We found that optogenetic stimulation of midbrain DA neurons was rewarding as assessed by optical intracranial self-stimulation (oICSS) in DAT-cre mice. \u0394\n                    <jats:sup>9<\/jats:sup>\n                    -THC and a PPAR\u03b3 (but not PPAR\u03b1) agonist dose-dependently inhibited oICSS. Pretreatment with PPAR\u03b1 or PPAR\u03b3 antagonists attenuated the \u0394\n                    <jats:sup>9<\/jats:sup>\n                    -THC-induced reduction in oICSS and \u0394\n                    <jats:sup>9<\/jats:sup>\n                    -THC-induced\u00a0anxiogenic effects. In addition, a PPAR\u03b3 agonist increased, while PPAR\u03b1 or PPAR\u03b3 antagonists decreased open-field locomotion. Pretreatment with PPAR\u03b1 or PPAR\u03b3 antagonists potentiated \u0394\n                    <jats:sup>9<\/jats:sup>\n                    -THC-induced hypoactivity and catalepsy but failed to alter \u0394\n                    <jats:sup>9<\/jats:sup>\n                    -THC-induced analgesia, hypothermia and immobility. These findings provide the first anatomical and functional evidence supporting an important role of PPAR\u03b1\/\u03b3 in DA-dependent behavior and cannabinoid action.\n                  <\/jats:p>","DOI":"10.1038\/s41380-023-02182-0","type":"journal-article","created":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T06:01:30Z","timestamp":1689919290000},"page":"4203-4214","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["PPAR\u03b1 and PPAR\u03b3 are expressed in midbrain dopamine neurons and modulate dopamine- and cannabinoid-mediated behavior in mice"],"prefix":"10.1038","volume":"28","author":[{"given":"Briana","family":"Hempel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline","family":"Crissman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sruti","family":"Pari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Hua","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Alton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6482-8104","authenticated-orcid":false,"given":"Zheng-Xiong","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,21]]},"reference":[{"key":"2182_CR1","unstructured":"Center for Behavioral Health Statistics and Quality. (2021). Results from the 2020 National Survey on Drug Use and Health: Detailed tables. Rockville, MD: Substance Abuse and Mental Health Services Administration; Retrieved from https:\/\/www.samhsa.gov\/data\/."},{"key":"2182_CR2","unstructured":"NCSL. State Medical Cannabis Laws. National Conference of State Legislatures. Washington, D.C. 2023."},{"key":"2182_CR3","doi-asserted-by":"publisher","first-page":"E112","DOI":"10.1208\/aapsj080113","volume":"8","author":"SR Childers","year":"2006","unstructured":"Childers SR. Activation of G-proteins in brain by endogenous and exogenous cannabinoids. AAPS J. 2006;8:E112\u2013E117.","journal-title":"AAPS J"},{"key":"2182_CR4","doi-asserted-by":"crossref","unstructured":"Pertwee RG. Pharmacological Actions of Cannabinoids. In: Pertwee RG, editor. Cannabinoids. Berlin, Heidelberg: Springer Berlin Heidelberg; 2005. p. 1\u201351.","DOI":"10.1007\/3-540-26573-2_1"},{"key":"2182_CR5","first-page":"275","volume":"93","author":"B Hempel","year":"2022","unstructured":"Hempel B, Xi Z-X. Receptor mechanisms underlying the CNS effects of cannabinoids: CB1 receptor and beyond. Adv Pharmacol (San Diego, Calif). 2022;93:275\u2013333.","journal-title":"Adv Pharmacol (San Diego, Calif)"},{"key":"2182_CR6","doi-asserted-by":"crossref","unstructured":"Howlett AC, Abood ME. Chapter Five - CB1 and CB2 Receptor Pharmacology. Adv Pharmacol. 2017;80:169\u2013206.","DOI":"10.1016\/bs.apha.2017.03.007"},{"key":"2182_CR7","doi-asserted-by":"crossref","unstructured":"Pertwee RG, Cascio MG. Endocannabinoids and Their Pharmacological Actions. Handb Exp Pharmacol. 2015:231;1\u201337.","DOI":"10.1007\/978-3-319-20825-1_1"},{"key":"2182_CR8","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.bbrc.2005.09.121","volume":"337","author":"SE O\u2019Sullivan","year":"2005","unstructured":"O\u2019Sullivan SE, Tarling EJ, Bennett AJ, Kendall DA, Randall MD. Novel time-dependent vascular actions of Delta9-tetrahydrocannabinol mediated by peroxisome proliferator-activated receptor gamma. Biochem Biophys Res Commun. 2005;337:824\u201331.","journal-title":"Biochem Biophys Res Commun"},{"key":"2182_CR9","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1111\/bph.13497","volume":"173","author":"SE O\u2019Sullivan","year":"2016","unstructured":"O\u2019Sullivan SE. An update on PPAR activation by cannabinoids. Br J Pharmacol. 2016;173:1899\u2013910.","journal-title":"Br J Pharmacol"},{"key":"2182_CR10","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1111\/bph.14339","volume":"176","author":"BN Okine","year":"2019","unstructured":"Okine BN, Gaspar JC, Finn DP. PPARs and pain. Br J Pharmacol. 2019;176:1421\u201342.","journal-title":"Br J Pharmacol"},{"key":"2182_CR11","doi-asserted-by":"publisher","first-page":"964","DOI":"10.2174\/1568026621666210521165532","volume":"21","author":"C Quiroga","year":"2021","unstructured":"Quiroga C, Barberena JJ, Alcaraz-Silva J, Machado S, Imperatori C, Yadollahpour A, et al. The Role of Peroxisome Proliferator-Activated Receptor in Addiction: A Novel Drug Target. Curr Top Med Chem. 2021;21:964\u201375.","journal-title":"Curr Top Med Chem"},{"key":"2182_CR12","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1210\/er.2018-00064","volume":"39","author":"N Bougarne","year":"2018","unstructured":"Bougarne N, Weyers B, Desmet SJ, Deckers J, Ray DW, Staels B, et al. Molecular Actions of PPAR\u03b1 in Lipid Metabolism and Inflammation. Endocr Rev. 2018;39:760\u2013802.","journal-title":"Endocr Rev"},{"key":"2182_CR13","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/j.2042-7158.2011.01432.x","volume":"64","author":"GQ Xiang","year":"2012","unstructured":"Xiang GQ, Tang SS, Jiang LY, Hong H, Li Q, Wang C, et al. PPAR\u03b3 agonist pioglitazone improves scopolamine-induced memory impairment in mice. J Pharm Pharmacol. 2012;64:589\u201396.","journal-title":"J Pharm Pharmacol"},{"key":"2182_CR14","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/npp.2014.268","volume":"40","author":"G de Guglielmo","year":"2015","unstructured":"de Guglielmo G, Melis M, De Luca MA, Kallupi M, Li HW, Niswender K, et al. PPAR\u03b3 Activation Attenuates Opioid Consumption and Modulates Mesolimbic Dopamine Transmission. Neuropsychopharmacology. 2015;40:927\u201337.","journal-title":"Neuropsychopharmacology"},{"key":"2182_CR15","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.biopsych.2010.12.010","volume":"69","author":"S Stopponi","year":"2011","unstructured":"Stopponi S, Somaini L, Cippitelli A, Cannella N, Braconi S, Kallupi M, et al. Activation of nuclear PPAR\u03b3 receptors by the antidiabetic agent pioglitazone suppresses alcohol drinking and relapse to alcohol seeking. Biol Psychiatry. 2011;69:642\u20139.","journal-title":"Biol Psychiatry"},{"key":"2182_CR16","doi-asserted-by":"publisher","first-page":"9864","DOI":"10.1523\/JNEUROSCI.1922-19.2019","volume":"39","author":"E Domi","year":"2019","unstructured":"Domi E, Caputi FF, Romualdi P, Domi A, Scuppa G, Candeletti S, et al. Activation of PPAR\u03b3 Attenuates the Expression of Physical and Affective Nicotine Withdrawal Symptoms through Mechanisms Involving Amygdala and Hippocampus Neurotransmission. J Neurosci. 2019;39:9864\u201375.","journal-title":"J Neurosci"},{"key":"2182_CR17","doi-asserted-by":"publisher","first-page":"5956","DOI":"10.1111\/bph.13352","volume":"172","author":"SP Alexander","year":"2015","unstructured":"Alexander SP, Cidlowski JA, Kelly E, Marrion N, Peters JA, Benson HE, et al. The Concise Guide to PHARMACOLOGY 2015\/16: Nuclear hormone receptors. Br J Pharmacol. 2015;172:5956\u201378.","journal-title":"Br J Pharmacol"},{"key":"2182_CR18","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1146\/annurev.med.53.082901.104018","volume":"53","author":"J Berger","year":"2002","unstructured":"Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med. 2002;53:409\u201335.","journal-title":"Annu Rev Med"},{"key":"2182_CR19","doi-asserted-by":"publisher","first-page":"236","DOI":"10.4103\/2231-4040.90879","volume":"2","author":"S Tyagi","year":"2011","unstructured":"Tyagi S, Gupta P, Saini AS, Kaushal C, Sharma S. The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases. J Adv Pharm Technol Res. 2011;2:236\u201340.","journal-title":"J Adv Pharm Technol Res"},{"key":"2182_CR20","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/sj.bjp.0707478","volume":"152","author":"Y Sun","year":"2007","unstructured":"Sun Y, Alexander SPH, Garle MJ, Gibson CL, Hewitt K, Murphy SP, et al. Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism. Br J Pharmacol. 2007;152:734\u201343.","journal-title":"Br J Pharmacol"},{"key":"2182_CR21","doi-asserted-by":"publisher","first-page":"23278","DOI":"10.1074\/jbc.M201084200","volume":"277","author":"KR Kozak","year":"2002","unstructured":"Kozak KR, Gupta RA, Moody JS, Ji C, Boeglin WE, DuBois RN, et al. 15-Lipoxygenase Metabolism of 2-Arachidonylglycerol: generation of a peroxisome proliferator-activated receptor \u03b1 agonist *. J Biol Chem. 2002;277:23278\u201386.","journal-title":"J Biol Chem"},{"key":"2182_CR22","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.neuropharm.2012.05.013","volume":"63","author":"G Fakhfouri","year":"2012","unstructured":"Fakhfouri G, Ahmadiani A, Rahimian R, Grolla AA, Moradi F, Haeri A. WIN55212-2 attenuates amyloid-beta-induced neuroinflammation in rats through activation of cannabinoid receptors and PPAR-\u03b3 pathway. Neuropharmacology. 2012;63:653\u201366.","journal-title":"Neuropharmacology"},{"key":"2182_CR23","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ejphar.2005.05.032","volume":"517","author":"M Bouaboula","year":"2005","unstructured":"Bouaboula M, Hilairet S, Marchand J, Fajas L, Fur GL, Casellas P. Anandamide induced PPAR\u03b3 transcriptional activation and 3T3-L1 preadipocyte differentiation. Eur J Pharmacol. 2005;517:174\u201381.","journal-title":"Eur J Pharmacol"},{"key":"2182_CR24","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1124\/mol.105.019117","volume":"70","author":"CE Rockwell","year":"2006","unstructured":"Rockwell CE, Snider NT, Thompson JT, Vanden Heuvel JP, Kaminski NE. Interleukin-2 Suppression by 2-Arachidonyl Glycerol Is Mediated through Peroxisome Proliferator-Activated Receptor \u03b3 Independently of Cannabinoid Receptors 1 and 2. Mol Pharmacol. 2006;70:101\u201311.","journal-title":"Mol Pharmacol"},{"key":"2182_CR25","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.tox.2014.09.011","volume":"326","author":"S Takeda","year":"2014","unstructured":"Takeda S, Ikeda E, Su S, Harada M, Okazaki H, Yoshioka Y, et al. \u03949-THC modulation of fatty acid 2-hydroxylase (FA2H) gene expression: Possible involvement of induced levels of PPAR\u03b1 in MDA-MB-231 breast cancer cells. Toxicology. 2014;326:18\u201324.","journal-title":"Toxicology"},{"key":"2182_CR26","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/j.1365-2990.2011.01248.x","volume":"38","author":"CB Carroll","year":"2012","unstructured":"Carroll CB, Zeissler M-L, Hanemann CO, Zajicek JP. \u03949-tetrahydrocannabinol (\u03949-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson\u2019s disease. Neuropathol Appl Neurobiol. 2012;38:535\u201347.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"2182_CR27","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.bbrc.2005.09.121","volume":"337","author":"SE O\u2019Sullivan","year":"2005","unstructured":"O\u2019Sullivan SE, Tarling EJ, Bennett AJ, Kendall DA, Randall MD. Novel time-dependent vascular actions of \u03949-tetrahydrocannabinol mediated by peroxisome proliferator-activated receptor gamma. Biochem Biophys Res Commun. 2005;337:824\u201331.","journal-title":"Biochem Biophys Res Commun"},{"key":"2182_CR28","doi-asserted-by":"publisher","first-page":"e618","DOI":"10.1038\/cddis.2013.141","volume":"4","author":"D Vara","year":"2013","unstructured":"Vara D, Morell C, Rodr\u00edguez-Henche N, Diaz-Laviada I. Involvement of PPAR\u03b3 in the antitumoral action of cannabinoids on hepatocellular carcinoma. Cell Death Dis. 2013;4:e618\u2013e618.","journal-title":"Cell Death Dis"},{"key":"2182_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/srep27618","volume":"6","author":"A Warden","year":"2016","unstructured":"Warden A, Truitt J, Merriman M, Ponomareva O, Jameson K, Ferguson LB, et al. Localization of PPAR isotypes in the adult mouse and human brain. Sci Rep. 2016;6:27618.","journal-title":"Sci Rep."},{"key":"2182_CR30","doi-asserted-by":"publisher","first-page":"107597","DOI":"10.1016\/j.neuropharm.2019.04.003","volume":"158","author":"CJ Jordan","year":"2019","unstructured":"Jordan CJ, Humburg B, Rice M, Bi G-H, You Z-B, Shaik AB, et al. The highly selective dopamine D3R antagonist, R-VK4-40 attenuates oxycodone reward and augments analgesia in rodents. Neuropharmacology. 2019;158:107597.","journal-title":"Neuropharmacology"},{"key":"2182_CR31","doi-asserted-by":"publisher","first-page":"8853","DOI":"10.1523\/JNEUROSCI.0988-20.2020","volume":"40","author":"E Galaj","year":"2020","unstructured":"Galaj E, Han X, Shen H, Jordan CJ, He Y, Humburg B, et al. Dissecting the Role of GABA Neurons in the VTA versus SNr in Opioid Reward. J Neurosci. 2020;40:8853\u201369.","journal-title":"J Neurosci"},{"key":"2182_CR32","doi-asserted-by":"publisher","first-page":"e13005","DOI":"10.1111\/adb.13005","volume":"26","author":"BA Humburg","year":"2021","unstructured":"Humburg BA, Jordan CJ, Zhang H-Y, Shen H, Han X, Bi G-H, et al. Optogenetic brain-stimulation reward: A new procedure to re-evaluate the rewarding versus aversive effects of cannabinoids in dopamine transporter-Cre mice. Addict Biol. 2021;26:e13005.","journal-title":"Addict Biol"},{"key":"2182_CR33","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1124\/pr.110.003004","volume":"62","author":"RG Pertwee","year":"2010","unstructured":"Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB(1) and CB(2). Pharm Rev. 2010;62:588\u2013631.","journal-title":"Pharm Rev"},{"key":"2182_CR34","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/nn.2874","volume":"14","author":"ZX Xi","year":"2011","unstructured":"Xi ZX, Peng XQ, Li X, Song R, Zhang HY, Liu QR, et al. Brain cannabinoid CB(2) receptors modulate cocaine\u2019s actions in mice. Nat Neurosci. 2011;14:1160\u20136.","journal-title":"Nat Neurosci"},{"key":"2182_CR35","doi-asserted-by":"publisher","first-page":"E5007","DOI":"10.1073\/pnas.1413210111","volume":"111","author":"HY Zhang","year":"2014","unstructured":"Zhang HY, Gao M, Liu QR, Bi GH, Li X, Yang HJ, et al. Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice. Proc Natl Acad Sci USA. 2014;111:E5007\u20135015.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2182_CR36","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1523\/JNEUROSCI.1493-22.2022","volume":"43","author":"X Han","year":"2023","unstructured":"Han X, Liang Y, Hempel B, Jordan CJ, Shen H, Bi GH, et al. Cannabinoid CB1 Receptors Are Expressed in a Subset of Dopamine Neurons and Underlie Cannabinoid-Induced Aversion, Hypoactivity, and Anxiolytic Effects in Mice. J Neurosci. 2023;43:373\u201385.","journal-title":"J Neurosci"},{"key":"2182_CR37","doi-asserted-by":"publisher","first-page":"108538","DOI":"10.1016\/j.neuropharm.2021.108538","volume":"189","author":"HY Zhang","year":"2021","unstructured":"Zhang HY, Shen H, Gao M, Ma Z, Hempel BJ, Bi GH, et al. Cannabinoid CB(2) receptors are expressed in glutamate neurons in the red nucleus and functionally modulate motor behavior in mice. Neuropharmacology. 2021;189:108538.","journal-title":"Neuropharmacology"},{"key":"2182_CR38","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s40263-019-00664-w","volume":"33","author":"E Galaj","year":"2019","unstructured":"Galaj E, Xi Z-X. Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders. CNS Drugs. 2019;33:1001\u201330.","journal-title":"CNS Drugs"},{"key":"2182_CR39","doi-asserted-by":"publisher","first-page":"S163","DOI":"10.1038\/sj.bjp.0706406","volume":"147","author":"RG Pertwee","year":"2006","unstructured":"Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol. 2006;147:S163\u2013S171.","journal-title":"Br J Pharmacol"},{"key":"2182_CR40","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1111\/bph.14625","volume":"176","author":"KJ Spiller","year":"2019","unstructured":"Spiller KJ, Bi G-h, He Y, Galaj E, Gardner EL, Xi Z-X. Cannabinoid CB1 and CB2 receptor mechanisms underlie cannabis reward and aversion in rats. Br J Pharmacol. 2019;176:1268\u201381.","journal-title":"Br J Pharmacol"},{"key":"2182_CR41","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.euroneuro.2020.11.019","volume":"43","author":"X Li","year":"2021","unstructured":"Li X, Hempel BJ, Yang H-J, Han X, Bi G-H, Gardner EL, et al. Dissecting the role of CB1 and CB2 receptors in cannabinoid reward versus aversion using transgenic CB1- and CB2-knockout mice. Eur Neuropsychopharmacol. 2021;43:38\u201351.","journal-title":"Eur Neuropsychopharmacol"},{"key":"2182_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-12399-z","volume":"7","author":"X Han","year":"2017","unstructured":"Han X, He Y, Bi G-H, Zhang H-Y, Song R, Liu Q-R, et al. CB1 Receptor Activation on VgluT2-Expressing Glutamatergic Neurons Underlies \u03949-Tetrahydrocannabinol (\u03949-THC)-Induced Aversive Effects in Mice. Sci Rep. 2017;7:12315.","journal-title":"Sci Rep."},{"key":"2182_CR43","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1210\/en.2008-0899","volume":"150","author":"DA Sarruf","year":"2009","unstructured":"Sarruf DA, Yu F, Nguyen HT, Williams DL, Printz RL, Niswender KD, et al. Expression of peroxisome proliferator-activated receptor-gamma in key neuronal subsets regulating glucose metabolism and energy homeostasis. Endocrinology. 2009;150:707\u201312.","journal-title":"Endocrinology"},{"key":"2182_CR44","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.neuroscience.2003.08.064","volume":"123","author":"S Moreno","year":"2004","unstructured":"Moreno S, Farioli-Vecchioli S, Ceru MP. Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience. 2004;123:131\u201345.","journal-title":"Neuroscience"},{"key":"2182_CR45","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1210\/endo.137.1.8536636","volume":"137","author":"O Braissant","year":"1996","unstructured":"Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology. 1996;137:354\u201366.","journal-title":"Endocrinology"},{"key":"2182_CR46","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.neuroscience.2004.09.043","volume":"130","author":"A Cimini","year":"2005","unstructured":"Cimini A, Benedetti E, Cristiano L, Sebastiani P, D\u2019Amico MA, D\u2019Angelo B, et al. Expression of peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RXRs) in rat cortical neurons. Neuroscience. 2005;130:325\u201337.","journal-title":"Neuroscience"},{"key":"2182_CR47","doi-asserted-by":"publisher","first-page":"12611","DOI":"10.1523\/JNEUROSCI.4127-15.2016","volume":"36","author":"E Domi","year":"2016","unstructured":"Domi E, Uhrig S, Soverchia L, Spanagel R, Hansson AC, Barbier E, et al. Genetic Deletion of Neuronal PPAR\u03b3 Enhances the Emotional Response to Acute Stress and Exacerbates Anxiety: An Effect Reversed by Rescue of Amygdala PPAR\u03b3 Function. J Neurosci. 2016;36:12611\u201323.","journal-title":"J Neurosci"},{"key":"2182_CR48","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1038\/npp.2012.123","volume":"37","author":"AA Rey","year":"2012","unstructured":"Rey AA, Purrio M, Viveros M-P, Lutz B. Biphasic Effects of Cannabinoids in Anxiety Responses: CB1 and GABAB Receptors in the Balance of GABAergic and Glutamatergic Neurotransmission. Neuropsychopharmacology. 2012;37:2624\u201334.","journal-title":"Neuropsychopharmacology"},{"key":"2182_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-14203-4","volume":"7","author":"S Bhattacharyya","year":"2017","unstructured":"Bhattacharyya S, Egerton A, Kim E, Rosso L, Riano Barros D, Hammers A, et al. Acute induction of anxiety in humans by delta-9-tetrahydrocannabinol related to amygdalar cannabinoid-1 (CB1) receptors. Sci Rep. 2017;7:15025.","journal-title":"Sci Rep."},{"key":"2182_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-022-02059-w","volume":"12","author":"E Galaj","year":"2022","unstructured":"Galaj E, Hempel B, Moore A, Klein B, Bi GH, Gardner EL, et al. Therapeutic potential of PIMSR, a novel CB1 receptor neutral antagonist, for cocaine use disorder: evidence from preclinical research. Transl Psychiatry. 2022;12:286.","journal-title":"Transl Psychiatry"},{"key":"2182_CR51","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.pbb.2015.05.002","volume":"134","author":"JK Gore-Langton","year":"2015","unstructured":"Gore-Langton JK, Flax SM, Pomfrey RL, Wetzell BB, Riley AL. Measures of the aversive effects of drugs: A comparison of conditioned taste and place aversions. Pharmacol Biochem Behav. 2015;134:99\u2013105.","journal-title":"Pharmacol Biochem Behav"},{"key":"2182_CR52","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/j.1369-1600.2007.00070.x","volume":"12","author":"TM Tzschentke","year":"2007","unstructured":"Tzschentke TM. Measuring reward with the conditioned place preference (CPP) paradigm: Update of the last decade. Addict Biol. 2007;12:227\u2013462.","journal-title":"Addict Biol"},{"key":"2182_CR53","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.biopsych.2010.07.009","volume":"69","author":"P Mascia","year":"2011","unstructured":"Mascia P, Pistis M, Justinova Z, Panlilio LV, Luchicchi A, Lecca S, et al. Blockade of Nicotine Reward and Reinstatement by Activation of Alpha-Type Peroxisome Proliferator-Activated Receptors. Biol Psychiatry. 2011;69:633\u201341.","journal-title":"Biol Psychiatry"},{"key":"2182_CR54","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1038\/sj.npp.1301213","volume":"32","author":"T Maeda","year":"2007","unstructured":"Maeda T, Kiguchi N, Fukazawa Y, Yamamoto A, Ozaki M, Kishioka S. Peroxisome Proliferator-Activated Receptor Gamma Activation Relieves Expression of Behavioral Sensitization to Methamphetamine in Mice. Neuropsychopharmacology. 2007;32:1133\u201340.","journal-title":"Neuropsychopharmacology"},{"key":"2182_CR55","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1210\/en.2011-1689","volume":"153","author":"KK Ryan","year":"2012","unstructured":"Ryan KK, Grayson BE, Jones KR, Schneider AL, Woods SC, Seeley RJ, et al. Physiological Responses to Acute Psychological Stress Are Reduced by the PPAR\u03b3 Agonist Rosiglitazone. Endocrinology. 2012;153:1279\u201387.","journal-title":"Endocrinology"},{"key":"2182_CR56","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1080\/15569543.2019.1673425","volume":"40","author":"F Beheshti","year":"2021","unstructured":"Beheshti F, Hosseini M, Hashemzehi M, Soukhtanloo M, Asghari A. The effects of PPAR-\u03b3 agonist pioglitazone on anxiety and depression-like behaviors in lipopolysaccharide injected rats. Toxin Rev. 2021;40:1223\u201332.","journal-title":"Toxin Rev"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-023-02182-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-023-02182-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-023-02182-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T05:05:29Z","timestamp":1706591129000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-023-02182-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,21]]},"references-count":56,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["2182"],"URL":"https:\/\/doi.org\/10.1038\/s41380-023-02182-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2614714\/v1","asserted-by":"object"}]},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,21]]},"assertion":[{"value":"22 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}